Mechanisms of Disease: angiogenesis and the management of breast cancer

被引：113

作者：

Banerjee, Susana ^{[1
]}

Dowsett, Mitch ^{[1
]}

Ashworth, Alan ^{[1
]}

Martin, Lesley-Ann ^{[1
]}

机构：

[1] Royal Marsden Hosp, Inst Canc Res, Acad Dept Biochem, London SW3 6JJ, England

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 09期

关键词：

bevacizumab; breast cancer; hypoxia; receptor tyrosine kinase; inhibitor; VeGF;

D O I：

10.1038/ncponc0905

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.

引用

页码：536 / 550

页数：15

共 117 条

[1] Targeting lymphangiogenesis to prevent tumour metastasis [J].

Achen, M. G. ;

Mann, G. B. ;

Stacker, S. A. .

BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1355-1360

[2]

[Anonymous], J CLIN ONCOL

[3] Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer [J].

Bando, H ;

Weich, HA ;

Brokelmann, M ;

Horiguchi, S ;

Funata, N ;

Ogawa, T ;

Toi, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (03) :553-561

[4] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[5] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[6] Maximizing the potential of bevacizumab in cancer treatment [J].

Bergsland, E ;

Dickler, MN .

ONCOLOGIST, 2004, 9 :36-42

[7] The multifaceted circulating endothelial cell in cancer: towards marker and target identification [J].

Bertolini, Francesco ;

Shaked, Yuval ;

Mancuso, Patrizia ;

Kerbel, Robert S. .

NATURE REVIEWS CANCER, 2006, 6 (11) :833-845

[8] HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors [J].

Blackwell, KL ;

Dewhirst, MW ;

Liotcheva, V ;

Snyder, S ;

Broadwater, G ;

Bentley, R ;

Lal, A ;

Riggins, G ;

Anderson, S ;

Vredenburgh, J ;

Proia, A ;

Harris, LN .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4083-4088

[9] Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy [J].

Bocci, G ;

Francia, G ;

Man, S ;

Lawler, J ;

Kerbel, RS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (22) :12917-12922

[10] Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma [J].

Bos, R ;

van der Groep, P ;

Greijer, AE ;

Shvarts, A ;

Meijer, S ;

Pinedo, HM ;

Semenza, GL ;

van Diest, PJ ;

van der Wall, E .

CANCER, 2003, 97 (06) :1573-1581

← 1 2 3 4 5 6 7 8 9 10 →